Faster Cardiac Answers with High‑Sensitivity Troponin

SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency.

PRNewsWire • Feb 19, 2026

QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference

SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference. The Company's presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m.

PRNewsWire • Feb 18, 2026

QDEL Expands Immunoassay Portfolio Via Lifotronic Supply Agreement

QuidelOrtho inks Lifotronic supply deal, adding 70+ assays and new analyzer platforms to boost global immunoassay reach and recurring revenue potential.

Zacks Investment Research • Feb 17, 2026

QuidelOrtho Q4 Earnings and Revenues Beat Estimates, Margins Down

QDEL beats Q4 estimates as Labs and global growth lift sales, but shrinking margins and respiratory weakness weigh on profits.

Zacks Investment Research • Feb 12, 2026

QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript

QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 12, 2026

QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagnostics business," said Brian J.

PRNewsWire • Feb 11, 2026

QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates

QuidelOrtho (QDEL) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.

Zacks Investment Research • Feb 11, 2026

Earnings Preview: QuidelOrtho (QDEL) Q4 Earnings Expected to Decline

QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 4, 2026

QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards

– First medical device company to receive excellence recognition in accordance with ISO 23592 – Gold Stevie® Award for Customer Service Success – Bronze Stevie® Award for AI & Tech Focused Digital Transformation Team of the Year SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") received the Excellence Services Label for its Customer and Technical Services in EMEA, awarded by the independent association Esprit de Service France, and in accordance with the international standard ISO 23592, a global framework for designing and delivering outstanding customer experiences. QuidelOrtho is the first medical device company to receive this distinction.

PRNewsWire • Feb 3, 2026

Strengthening the blood supply: Awareness, challenges and donor impact

SAN DIEGO, Jan. 22, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. With decades of experience in blood banking and immunohematology, Mullens shares insights into the pressures on today's blood supply and the importance of consistent donor engagement.

PRNewsWire • Jan 22, 2026